Find out how to recognize symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP) and differentiate it from other neuromuscular disorders. Expert faculty discuss how to overcome diagnostic challenges to arrive at an accurate diagnosis earlier and break down the considerations for IVIG vs SCIG treatment for CIDP. Don’t miss this opportunity to enhance your clinical practice and positively impact the lives of your patients.
Innovations in Ig Treatments in CIDP
Learn how to better recognize symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP) and explore Ig treatment options.
Live
Broadcast
Information
March 26, 2025
12:00 PM - 01:00 PM EDT
Virtual
Share
This broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Share
Share
Share this program on:
Details
Presenters
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Claudia Sommer, MD
Speaker of the Clinical Research Unit
Consultant, Department of Neurology
The University Hospital of Würzburg
Würzburg, Germany
Dr. Sommer has reported the following relevant financial relationships or relationships with ineligible companies or any amount during teh past 24 months:
Consulting Fees: Akigai, Alnylam, Annexon, Argenx, CSL Behring, Grifols, Kedriron, Nevro, Sanofi, Takeda, Teva
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Rosanne Strauss, PharmD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Identify key diagnostic pitfalls in chronic inflammatory demyelinating polyneuropathy (CIDP) to improve recognition and reduce misdiagnosis rates
- Compare the clinical features of CIDP with overlapping neuromuscular disorders to enhance diagnostic accuracy
- Educate on clinical scenarios that help stratify CIDP patients for IVIG or SCIG treatment options
Target Audience
This activity has been designed to meet the educational needs of neurologists and infusion specialists as well as all other physician associates, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-042-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Takeda Pharmaceuticals USA, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Overview
Find out how to recognize symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP) and differentiate it from other neuromuscular disorders. Expert faculty discuss how to overcome diagnostic challenges to arrive at an accurate diagnosis earlier and break down the considerations for IVIG vs SCIG treatment for CIDP. Don’t miss this opportunity to enhance your clinical practice and positively impact the lives of your patients.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Claudia Sommer, MD
Speaker of the Clinical Research Unit
Consultant, Department of Neurology
The University Hospital of Würzburg
Würzburg, Germany
Dr. Sommer has reported the following relevant financial relationships or relationships with ineligible companies or any amount during teh past 24 months:
Consulting Fees: Akigai, Alnylam, Annexon, Argenx, CSL Behring, Grifols, Kedriron, Nevro, Sanofi, Takeda, Teva
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Rosanne Strauss, PharmD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Identify key diagnostic pitfalls in chronic inflammatory demyelinating polyneuropathy (CIDP) to improve recognition and reduce misdiagnosis rates
- Compare the clinical features of CIDP with overlapping neuromuscular disorders to enhance diagnostic accuracy
- Educate on clinical scenarios that help stratify CIDP patients for IVIG or SCIG treatment options
Target Audience
This activity has been designed to meet the educational needs of neurologists and infusion specialists as well as all other physician associates, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-042-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Takeda Pharmaceuticals USA, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
CME/CEChairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
0.25 credits
Mazen Noureddin, MD, MHSc
0.25 creditsEvolving Strategies for Sustained-Release Glaucoma Treatments
Evolving Strategies for Sustained-Release Glaucoma Treatments
MinuteCE®Evolving Strategies for Sustained-Release Glaucoma Treatments
1.00 program creditSarah H. Van Tassel, MD
Justin Schweitzer, OD, FAAO
1.00 program creditWhat’s New in Schlemm’s Canal MIGS?
What’s New in Schlemm’s Canal MIGS?
MinuteCE®What’s New in Schlemm’s Canal MIGS?
1.00 program credit
Paul Petrakos, DO, MS
I. Paul Singh, MD
1.00 program creditWhat’s New in Subconjunctival MIBS
What’s New in Subconjunctival MIBS
MinuteCE®What’s New in Subconjunctival MIBS
1.00 program creditPaul Petrakos, DO, MS
I. Paul Singh, MD
1.00 program credit